Concerns about the danger posed by the Omicron SARS-CoV2 variant have gripped the world in the last week, even while public health scientists and biopharma researchers race to establish if, as feared, it proves to be more transmissible than previous variants and potentially evade existing vaccines.
But just as at the outset of the pandemic in early 2020, a handful of biopharma companies who might have...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
